SCLN
Income statement / Annual
Last year (2016), SciClone Pharmaceuticals, Inc.'s total revenue was $160.10 M,
an increase of 1.81% from the previous year.
In 2016, SciClone Pharmaceuticals, Inc.'s net income was $30.73 M.
See SciClone Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
FY-2011
|
FY-2010
|
FY-2009
|
FY-2008
|
FY-2007
|
| Period Ended |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
12/31/2011 |
12/31/2010 |
12/31/2009 |
12/31/2008 |
12/31/2007 |
| Operating Revenue |
$160.10 M |
$157.26 M |
$134.79 M |
$127.06 M |
$156.27 M |
$133.64 M |
$85.11 M |
$72.41 M |
$54.11 B |
$37.06 B |
| Cost of Revenue |
$22.90 M
|
$22.35 M
|
$23.00 M
|
$17.67 M
|
$22.00 M
|
$0.00
|
$12.69 M
|
$11.96 M
|
$9.83 B
|
$6.74 B
|
| Gross Profit |
$137.20 M
|
$134.91 M
|
$111.79 M
|
$109.39 M
|
$134.27 M
|
$133.64 M
|
$72.42 M
|
$60.45 M
|
$44.29 B
|
$30.32 B
|
| Gross Profit Ratio |
0.86
|
0.86
|
0.83
|
0.86
|
0.86
|
1
|
0.85
|
0.83
|
0.82
|
0.82
|
| Research and Development Expenses |
$15.08 M
|
$12.31 M
|
$14.58 M
|
$7.46 M
|
$1.00 M
|
$12.35 M
|
$12.42 M
|
$16.53 M
|
$23.22 B
|
$16.94 B
|
| General & Administrative Expenses |
-$20.52 M
|
-$26.06 M
|
-$25.73 M
|
-$23.33 M
|
-$48.89 M
|
-$24.82 M
|
$15.61 M
|
-$6.28 M
|
-$5.47 B
|
-$3.68 B
|
| Selling & Marketing Expenses |
$54.70 M
|
$53.96 M
|
$48.48 M
|
$55.82 M
|
$70.33 M
|
$48.86 M
|
$0.00
|
$18.81 M
|
$17.33 B
|
$13.93 B
|
| Selling, General & Administrative Expenses |
$34.18 M
|
$27.90 M
|
$22.75 M
|
$32.50 M
|
$21.44 M
|
$24.03 M
|
$15.61 M
|
$12.52 M
|
$11.86 B
|
$10.25 B
|
| Other Expenses |
$54.70 M
|
$64.79 M
|
$33.90 M
|
$48.36 M
|
$70.33 M
|
$36.51 M
|
$22.01 M
|
$18.81 M
|
$17.33 B
|
$14.44 B
|
| Operating Expenses |
$103.96 M
|
$105.00 M
|
$71.22 M
|
$88.32 M
|
$92.77 M
|
$72.89 M
|
$50.03 M
|
$47.86 M
|
$52.40 B
|
$41.62 B
|
| Cost And Expenses |
$126.86 M
|
$127.35 M
|
$94.23 M
|
$105.99 M
|
$114.77 M
|
$72.89 M
|
$62.72 M
|
$59.82 M
|
$62.23 B
|
$48.35 B
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$195.00 K
|
$179.00 K
|
$31.00 M
|
$20.00 M
|
| Depreciation & Amortization |
$985.00 K
|
$931.00 K
|
$852.00 K
|
$860.00 K
|
$3.45 M
|
$2.94 M
|
$556.00 K
|
$530.00 K
|
$353.00 M
|
$95.00 M
|
| EBITDA |
$35.12 M |
$31.20 M |
$27.23 M |
$14.07 M |
$9.72 M |
$32.20 M |
$24.01 M |
$13.30 M |
-$7.49 B |
-$9.53 B |
| EBITDA Ratio |
0.22
|
0.2
|
0.2
|
0.11
|
0.06
|
0.24
|
0.28
|
0.18
|
-0.14
|
-0.26
|
| Operating Income Ratio |
0.21
|
0.19
|
0.19
|
0.08
|
0.04
|
0.22
|
0.26
|
0.17
|
-0.16
|
-0.3
|
| Total Other Income/Expenses Net |
$898.00 K
|
$359.00 K
|
$393.00 K
|
$2.78 M
|
-$138.00 K
|
-$163.00 K
|
$863.00 K
|
-$8.00 K
|
$561.00 M
|
$1.65 B
|
| Income Before Tax |
$34.13 M
|
$30.27 M
|
$26.38 M
|
$13.21 M
|
$6.27 M
|
$29.26 M
|
$23.26 M
|
$12.59 M
|
-$7.87 B
|
-$9.65 B
|
| Income Before Tax Ratio |
0.21
|
0.19
|
0.2
|
0.1
|
0.04
|
0.22
|
0.27
|
0.17
|
-0.15
|
-0.26
|
| Income Tax Expense |
$3.40 M
|
$807.00 K
|
$1.17 M
|
$2.24 M
|
-$3.35 M
|
$798.00 K
|
$2.18 M
|
$641.00 K
|
$475.00 M
|
$301.00 M
|
| Net Income |
$30.73 M
|
$29.46 M
|
$25.21 M
|
$10.96 M
|
$9.62 M
|
$28.46 M
|
$21.08 M
|
$11.95 M
|
-$8.35 B
|
-$9.95 B
|
| Net Income Ratio |
0.19
|
0.19
|
0.19
|
0.09
|
0.06
|
0.21
|
0.25
|
0.16
|
-0.15
|
-0.27
|
| EPS |
0.61 |
0.59 |
0.49 |
0.2 |
0.17 |
0.5 |
0.44 |
0.26 |
-180.64 |
-215.79 |
| EPS Diluted |
0.58 |
0.56 |
0.48 |
0.2 |
0.16 |
0.48 |
0.43 |
0.25 |
-180.64 |
-215.79 |
| Weighted Average Shares Out |
$50.24 M
|
$49.80 M
|
$51.28 M
|
$53.59 M
|
$56.64 M
|
$57.47 M
|
$47.62 M
|
$46.57 M
|
$46.21 M
|
$46.10 M
|
| Weighted Average Shares Out Diluted |
$52.57 M
|
$52.17 M
|
$52.68 M
|
$54.94 M
|
$58.48 M
|
$59.61 M
|
$49.41 M
|
$47.40 M
|
$46.21 M
|
$46.10 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
